Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer
Authors
-
Yelena A. Lunyova
Voronezh State Medical University named after N.N. Burdenko
https://orcid.org/0000-0002-6077-3043
DOI:
https://doi.org/10.18413/rrpharmacology.9.10037Abstract
Introduction: In recent decades, pharmacoeconomic analysis of multiple diseases has significantly progressed; in particular, the most prevalent one is the cost-effectiveness analysis. Chemotherapy remains the leading and most effective treatment option for small cell lung cancer, which accounts for more than a quarter of all other forms of respiratory cancers.
Materials and Methods: An assessment of the incidence of lung cancer and its probable causes was carried out. The main methods used in the study were cost-of-treatment analysis, ABC/VEN analysis and cost-effectiveness analysis. Survival rates (number of years or months, interval and average number of years/ months) and the cost of a month of life were also evaluated.
Discussion: The results obtained on the basis of a questionnaire survey of patients with lung cancer demonstrate that smoking is the leading risk factor – 24.9% of the pro rata contribution. The author identified the most expensive drugs, costing 60-80% of the budget, that is scheme 2 ‘etoposide + carboplatin’, and the least expensive drugs, costing 5-10% of the budget, which are auxiliary drugs. According to the study results, patients managed following a chemotherapy regimen ‘etoposide + carboplatin’ have the highest survival rate at the highest cost of treatment compared to patients following a chemotherapy regimen ‘cyclophosphamide + doxorubicin + vincristine’, which is the least expensive.
Conclusion: Evidence-based comprehensive pharmacoeconomic model for evaluation of drug supply for chemotherapy in small cell lung cancer improves registration of history cases and allows for pharmacoeconomic cost-effectiveness analysis considering features of each patient.
Graphical Abstract
Keywords:
small cell lung cancer, chemotherapy, cost-effectiveness, pharmacoeconomics, ABC/VEN analysis, cost of the survived monthReferences
Anoshkina EV (2020) The role of pharmacoeconomical research in optimizing the quality of drug care. Eurasian Scientific Association [Evraziiskoe Nauchnoe Ob"edinenie] 9-3(67): 244–248. [in Russian]
Avksentiev NA, Frolov MYu, Makarov AS (2019) Pharmacoeconomical study of the use of pembrolizumab and nivolumab in second-line therapy of advanced non-small cell lung cancer. Effective Pharmacotherapy [Effektivnaya Farmakoterapiya] 15(24): 38–47. https://doi.org/10.33978/2307-3586-2019-15-24-38-46 [in Russian]
Bagrova SG, Bychkov MB, Gorbunova VA, Kuzminov AE, Naskhletashvili DR (2013) Comparative evaluation of various platinum-containing chemotherapy regimens in the treatment of advanced small cell lung cancer (experience of the Chemotherapy Department of N. N. Blokhin Russian Research Medical Center of the Russian Academy of Medical Sciences). Russian Journal of Oncology [Rossiiskii Onkologicheskii Zhurnal] 2: 4–10. [in Russian]
Chen KN (2016) Small cell lung cancer and TNM staging. Chinese Journal of Lung Cancer 19(6): 409–412. https://doi.org/10.3779/j.issn.1009-3419.2016.06.22 [PubMed] [PMC]
Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruysscher D, Van Schil PE, Vansteenkiste J, Reck M; ESMO Guidelines Committee (2021) Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 32(7): 839–853. https://doi.org/10.1016/j.annonc.2021.03.207 [PubMed] [PMC]
Esakov YuS, Shriner IV, Kirpichnikova EI, Kulikova EA, Efteev LA, Tukvadze ZG, Khvedelidze GV, Galkin VN (2022) Clinical efficacy of ct-guided transthoracic needle biopsy of peripheral lung lesions. Pirogov Russian Journal of Surgery [Khirurgiya. Zurnal im. N.I. Pirogova] 5: 34–42. https://doi.org/10.17116/hirurgia202205134[in Russian]
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group (2013) Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 6: vi99–105. https://doi.org/10.1093/annonc/mdt178 [PubMed]
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators (2018) Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. The New England Journal of Medicine 378: 2078–2092. https://doi.org/10.1056/NEJMoa1801005[PubMed]
Grygoruk OG, Tsoi DA, Bazulina LM, Vihlyanov IV (2022) Small-cell lung carcinoma. Cytological diagnostics. Malignant Tumors [Zlokachestvennye Opukholi] 12(1): 36–43. https://doi.org/10.18027/2224-5057-2022-12-1-36-43 [in Russian]
Gimalova GF, Abdullin ZS, Khusnutdinova EK (2020) MLPA-analysis of the TP53 gene in patients with small-cell lung cancer. Medical Genetics [Meditsinskaya Genetika] 19-6(215): 83–85. https://doi.org/10.25557/2073-7998.2020.06.83-85 [in Russian]
Kosterina NE, Grinberg LM (2019) Cytological research methods in complex morphological diagnosis of small cell lung cancer on ”small specimens”. Ural Medical Journal [Ural'skii Meditsinskii Zhurnal] 10(178): 23–27.https://doi.org/10.25694/URMJ.2019.10.18 [in Russian]
Kuzminov AE, Laktionov KK, Egorova AV, Breder VV, Barbolina TD (2019) Immunotherapy for small-cell lung cancer. Medical Council [Meditsinskii Sovet] 10: 22–27. https://doi.org/10.21518/2079-701X-2019-10-22-27 [in Russian]
Kuzminov AE, Borisova TN, Breder VV, Reutova EV, Barbolina TD, Laktionov KK (2020) Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment. Medical Council [Meditsinskii Sovet] (9): 190–195. https://doi.org/10.21518/2079-701X-2020-9-190-195 [in Russian]
Makimbetov EK, Dzhunushalieva GS (2015) The state of oncopediatric service and epidemiology of malignant neoplasms in the Kyrgyz Republic. Oncopediatrics [Onkopediatriya] 2(3): 292–294. [in Russian]
Meijer JJ, Leonetti A, Airò G, Tiseo M, Rolfo C, Giovannetti E, Vahabi M (2022). Small cell lung cancer: Novel treatments beyond immunotherapy. Seminars in Cancer Biology 86(Pt 2): 376–385. https://doi.org/10.1016/j.semcancer.2022.05.004 [PubMed]
Mukhambetzhan AZh, Urazaeva ST, Urazaeva ON, Tusupkalieva KSh, Begalin TB, Amanshieva AA, Tashimova ZhK, Kumar GB, Nurmukhamedova ShM (2020) Modern ideas about epidemiology and risk factors for lung cancer. Literature review. Science and Health [Nauka i Zdravoohranenie] 2: 27–37. https://doi.org/10.34689/SH.2020.22.2.003 [in Russian]
Napreenko IV, Asimova LF, Satyreva AV (2020) Comparative evaluation of the effectiveness and toxicity of various chemotherapy regimens in the treatment of small cell lung cancer (according to the literature). Student Bulletin [Studencheskii Byulleten'] 44-4(142): 70–73. [in Russian]
Petrov VI (2022) Pharmacologistics - a new paradigm in clinical pharmacology. Bulletin of the Volgograd State Medical University [Vestnik Volgogradskogo Gosudarstvennogo Meditsinskogo Universiteta] 19(2): 3–6. https://doi.org/10.19163/1994-9480-2022-19-2-3-6 [in Russian]
Skurikhin EG, Pershina OV, Pakhomova AV, Ermakova NN, Zhukova MA, Goldberg VE, Simolina EI, Pan ES, Morozov SG, Kubatiev AA, Dygai AM (2022) Stem tumor cells as a potential diagnostic marker and drug target in small cell lung cancer. Questions of Oncology [Voprosy Onkologii] 68(S3): 492–493 [in Russian]
Skurikhin EG, Zhukova MA, Dygai AM (2022) Prospects of using programmed CD8+ T-lymphocytes in the treatment of small cell lung cancer. Genes and Cells [Gheny i Kletki] 17 (3): 212–213. https://doi.org/10.23868/gc123521 [in Russian]
Svistunov AA, Yagudina RI, Abdrashitova GT, Babiy VV, Makarova EI, Pochuprina AA, Rybchenko YuV, Tolordava GA, Ugrekhelidze DT (2016) Features of pharmacoeconomical analysis in various nosologies. The Sechenov Medical Journal [Sechenoskii Vestnik] 2 (24): 42–50. [in Russian]
Tsiouprou I, Zaharias A, Spyratos D (2019) The role of immunotherapy in extensive stage small-cell lung cancer: A review of the literature. Canadian Respiratory Journal 2019: 6860432. https://doi.org/10.1155/2019/6860432[PubMed] [PMC]
Ulumbekova GE, Alvianskaya NV, Petrachkov IV (2022) Organization and financing of cancer care in the Russian Federation in 2018-2024. Healthcare Management: News. Views. Education Bulletin of the Higher School of Healthcare Organization and Management [Orgzdrav: Novosti, Mneniya, Obuchenie. Vestnik Vshouz] 8(1): 33–74. https://doi.org/10.33029/2411-8621-2022-8-1-33-74 [in Russian]
Yagudina RI, Gavrilina NI (2022) The use of the MIN-MAX method in assessing the effectiveness of healthcare and drug provision of the population. Remedium 26(2): 139–142. https://doi.org/10.32687/1561-5936-2022-26-2-139-142 [in Russian]
Yagudina RI, Skulkova RS (2011) Fundamentals of pharmacoeconomical analysis. Bulletin of the Scientific Center for the Examination of Medical Products [Vestnik Nauchnogo Tsentra Ekspertizy Meditsinskikh Izdelii] 2: 56–59. [in Russian]
Yang S, Zhang Z, Wang Q (2019) Emerging therapies for small cell lung cancer. Journal of Hematology and Oncology 2-12(1): 47. https://doi.org/10.1186/s13045-019-0736-3 [PubMed] [PMC]
Yarovoy SK, Shikina IB (2020) Pharmacoeconomical efficiency of chemotherapy of malignant neoplasms of bronchi and lungs. Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology [Farmakoekonomika. Sovremennaya Farmakoekonomika i Farmakoepidemiologiya] 13(1): 13–22. https://doi.org/10.17749/2070-4909.2020.13.1.13-22 [in Russian]
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Research Results in Pharmacology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Русский
English
